XOMA Royalty Corp Enters Definitive Merger Agreement with Ligand Pharmaceuticals for $39/Share Cash Plus CVR

summarizeSummary

XOMA Royalty Corp has filed definitive proxy materials detailing its merger agreement with Ligand Pharmaceuticals, where shareholders will receive $39.00 per share in cash plus a Contingent Value Right (CVR) tied to litigation proceeds.

check_boxKey Events

• Definitive Merger Agreement Signed

  XOMA Royalty Corp. has entered into a definitive Agreement and Plan of Merger to be acquired by Ligand Pharmaceuticals Incorporated.

• Cash and Contingent Value Right (CVR) Consideration

  Shareholders will receive $39.00 per share in cash, plus one non-transferable CVR per share. The CVR entitles holders to a portion of 75% of net proceeds from pending Janssen Litigation.

• Significant Shareholder Support

  Entities affiliated with BVF Partners, owning approximately 47% of XOMA's outstanding shares (including converted preferred stock), have signed voting agreements in support of the transaction.

• Unanimous Board Approval

  The transaction has been unanimously approved by XOMA Royalty's Board of Directors.

auto_awesomeAnalysis

This DEFA14A filing provides the full definitive merger agreement, detailing the terms under which Ligand Pharmaceuticals will acquire XOMA Royalty Corp. for $39.00 per share in cash, plus a Contingent Value Right (CVR) per share. The CVR offers shareholders potential upside from the ongoing Janssen Litigation. The agreement is unanimously approved by XOMA's Board and significantly bolstered by voting support agreements from key stockholders, representing approximately 47% of outstanding shares, making shareholder approval highly probable. The transaction, valued at approximately $739 million, represents a substantial premium to XOMA Royalty's recent trading average and is a transformative event for the company, providing a clear exit for shareholders with additional contingent value.